Skip to content
lifestyle.onebyfourstudio.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Satellos Bioscience Inc.
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
September 24, 2026
Satellos to Present at the 31st Annual Congress of the World Muscle Society
September 15, 2026
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
September 9, 2026
Satellos to Participate in Upcoming Investor Conferences
September 1, 2026
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
August 13, 2026
Satellos to Participate in Upcoming Investor Conferences
May 27, 2026
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
May 24, 2026
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 9, 2026
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
March 27, 2026
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
March 10, 2026